Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Drug Profile

Setrusumab - Mereo BioPharma/Ultragenyx Pharmaceutical

Alternative Names: Anti-sclerostin-monoclonal-antibody-Mereo; BPS-804; UX-143

Latest Information Update: 17 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Mereo BioPharma; Novartis; Ultragenyx Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Osteogenesis imperfecta
  • Discontinued Hypophosphatasia; Postmenopausal osteoporosis

Most Recent Events

  • 14 Oct 2023 Efficacy and adverse event data from a phase II/III trial in Osteogenesis imperfecta released by Ultragenyx Pharmaceutical
  • 14 Jun 2023 Phase-III clinical trials in Osteogenesis imperfecta (In children) in Italy, Canada, Brazil (IV) (NCT05768854)
  • 14 Jun 2023 Phase-III clinical trials in Osteogenesis imperfecta (In children) in Poland, Netherlands, France (IV) (NCT05768854)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top